Top Markets
Coin of the day
Solvonis Therapeutics plc Solvonis Therapeutics plc

Solvonis Therapeutics plc

SVNS
Classement en actions #40468
Graft Polymer (UK) Plc, set to become Solvonis Therapeutics plc in January... Graft Polymer (UK) Plc, set to become Solvonis Therapeutics plc in January 2025, is dedicated to the research and development of advanced polymer modification technologies and techniques. Its operations span the United Kingdom, Slovenia, and across Europe. The company offers a diverse portfolio of specialized products: GRAFTABOND: A line of graft/block copolymers designed to robustly combine various polymers with materials such as fiberglass, carbon fiber, mineral and natural fillers, and even mixed polymer waste. GRAFTALEN: These are reactive solid super-concentrates engineered to enhance polyolefin rheology, boost e-modulus, act as chain extenders for PET/PBT, and serve as AOX masterbatches. GRAFTAPOR: Comprising porous polymer-carriers, this line is specifically developed for applications involving liquid chemicals. GRAFTAMID: This series includes high-temperature elastomers, based on nanostructured polyolefin-polyamide alloys. They function as advanced hardening modifiers within polyamide compounds or as standalone components in hot melt adhesive formulations. GRAFTAKIT: Offering reactive liquid or solid super-concentrates embedded in polymeric porous media, GRAFTAKIT is used to optimize reaction extrusion and the modification of compounds. GRAFTALLOY: A range of polymer-polymer nano-alloys crafted to significantly improve abrasion and temperature resistance, boost impact strength, and reduce friction. GRAFTASYNT: This line encompasses synthetic products, notably including halogen-free flame retardants. GRAFTAMER: An innovative smart polymer characterized by thermo-reversible crosslinking, self-hardening, self-healing properties, and shape memory capabilities. The company was founded in 2017 and maintains its headquarters in London, United Kingdom.
Prix de l'action
$0.00204105
Capitalisation boursière
$138.92K
Changement (1 jour)
5.63%
Changement (1 an)
-60.44%
Pays
GB
Échange Solvonis Therapeutics plc (SVNS)

Catégorie

Le prix SVNS avec la capitalisation boursière de B
Solvonis Therapeutics plc Solvonis Therapeutics plc
SVNS
$0.00204105
Capitalisation boursière de Solvonis Therapeutics plc(SVNS)
Capitalisation boursière: $138.92K
En August 2026, Solvonis Therapeutics plc a une capitalisation boursière de $138.92K. Cela fait de Solvonis Therapeutics plc la 40468th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Solvonis Therapeutics plc du 2022 au 2026
SVNS par rapport au top 5 des plus populaires stocks
Prix pour SVNS L’actif B La capitalisation boursière de B Résultats
Solvonis Therapeutics plc Solvonis Therapeutics plc
$80,358.71 $138.92K
$5.470T +3,937,121,289.65%
Solvonis Therapeutics plc Solvonis Therapeutics plc
$65,630.42 $138.92K
$4.467T +3,215,518,705.67%
Solvonis Therapeutics plc Solvonis Therapeutics plc
$61,287.49 $138.92K
$4.171T +3,002,739,654.88%
Solvonis Therapeutics plc Solvonis Therapeutics plc
$54,361.71 $138.92K
$3.700T +2,663,415,733.27%
Solvonis Therapeutics plc Solvonis Therapeutics plc
$41,936.14 $138.92K
$2.854T +2,054,633,061.29%